ESMERALDA GALLEMORE – FOUNDER / NUTRITIONAL EXPERT
Esmeralda Gallemore is nationally recognized for her contributions in the field of nutrition. She is a spokesperson for nutrition and wellness living, particularly related to eye health. Esmeralda attended the prestigious Institute For Integrative Nutrition (IIN) in New York City, where she became a certified health coach (INHC). She is an expert in nutrition and healthy eating, as well as entrepreneurship and coaching skills. As an INHC, she uses holistic methods to foster behavioral changes for improved nutrition, healthier eating habits, physical aptitude and overall greater health and wellness. To further enhance her skills, she completed an Advanced Education degree in Psychology On Eating Disorders. Esmeralda began her career in the field of ophthalmology, specifically retina, focusing her expertise on retinal angiography, eye health and eyesight. She completed a two-year ophthalmology clinical program at the UCLA Jules Stein Eye Institute under the supervision of Director Kevin Miller, MD and Bobby Ballenberg, COT.
From 2003 to 2006, she worked at the prestigious Retina Vitreous Associates Group as a clinical back office trainer consultant. She is an internationally-recognized lecturer with the Joint Commission of Allied Personnel In Ophthalmology (JCAHPO), Association of Technical Personnel in Ophthalmology (ATPO), American Society of Ophthalmic Administrators (ASOA) and Ophthalmic Photographers’ Society (OPS). She founded two thriving ocular vitamin corporations which as of 2020 have been consolidated into Eyes and Body.com. She is recognized in the field of eye-care for her accomplishments, with top selling health formulations: “Macula and Body Health Complete,” “Omega-3 DHA Advanced,” “Urge-Vite NAD+,” “Slumber-Vite,” “Diabetic and body Health Complete,” and “Vision and Body.” When she consolidated her companies, she enhanced her top formulas to optimize full body wellness. The new and improved “Macula and Body Health Complete” contains Nicotinamide Riboside (NR) (scientifically proven to increase NAD and restore mitochondrial cells) as well as higher levels of Zinc to help prevent the progression of macular degeneration. “Urge-Vite NAD+” has been upgraded to an anti-aging agent. It also contains the powerful NR ingredient, which has been shown to improve balance testosterone and estrogen levels, enhance performance, and improve sleep. “Eyes, Hair and Body” is an all in one formula for full body wellness, especially enhancing skin, hair and nail health. “Nutri-Pick Me Up” contains high levels of anti-oxidants like turmeric, ginger, fulvic acid, and humic minerals. It is a popular powder energy mix to optimize hydration on the go.
In 2007, Esmeralda co-founded Retina Macula Institute in Torrance, CA, where she had the privilege to work alongside co-founder Dr. Ron Gallemore MD, PhD.Under Dr. Gallemore’s supervision, Esmeralda published and co-authored multiple scientific journals: “Combined Scleral Flap with Donor Scleral Patch Graft for Anterior Tube Placement in Glaucoma Drainage Device Surgery,” Case Reports in Ophthalmological Medicine, vol. 2016 published by Hindawi Publishing Corporation, “Photodynamic therapy combined with antivascularendothelial growth factor treatment for recalcitrant chronic central serous chorioretinopathy” published in Dove Press Journal: Clinical Ophthalmology, “Silicone oil droplets following intravitreal bevacizumab injections,” published in the American Journal of Ophthalmology Case Reports 2018. Esmeralda also compiled power-point presentations, both as an angiographer and as co-lecturer, for case presentations in the journal Retina.
During her tenure at Retina Macula Institute, she established a new clinical research department and worked as both the clinical research coordinator and as the general clinical research administrator. She recruited and trained a team of students to understand protocols, clinical conducts, schedule visits, prepare consents, and log medications.
Through perseverance, dedication and determination, Esmeralda created a teaching institute to share her devotion to ophthalmology. She is considered one of the top trainers nationally and globally in the field of retina. Her specialties are performing IV’s, Fundus Autofluorescence Imaging, Fluorescein and Indocyanine Green Angiography, Retinal Fundus Photography, B-Scan Imaging (Eye Cubed), and Optical Coherence Tomography (ONH, macula).
She has taught protocols and analysis of ERGs, VEPs, EOGs, multi focal ERGs, slit lamp exams, visual fields (Goldmann, Octopus 1-2-3, Humphrey).
Esmeralda has taught hundreds of undergraduate students from elite universities such as University of California Los Angeles (UCLA), Princeton University (PU), University of Southern California (USC), Stanford University, Western University of Health Sciences, University of California San Diego (UCSD), University of California Irvine (UCI), and University of California Riverside (UCR).
Under Esmeralda’s guidance, Retina Macula Institute had a two-year training program teaching retinal angiography, starting IV’s, identifying retinal disorders performing patient work-ups, manifest refractions, clinical research and publications.
Esmeralda has authored four books, three non-fiction and one children’s fiction anthology: “The Work-Up Of The Retina Patient: So you Think you Can Tech,” editions one and two. “So You Think You Know Vitamins: The ABC’s of Nutrition,” and, “So You Think You Can Laugh: Adventures of Braden, Gigi and Tiger.”
Esmeralda is a certified life and health coach and continues to practice management consulting. She is a liaison between patients, vendors, and other medical professionals. She guides people in need to surpass their goals and create a healthier version of themselves.
Some of the clinical trials that Esmeralda participated in are noted below:
(GRA) General Research Administrator/(CRC) Clinical research coordinator
Study Investigating High Resolution OCT, Multifocal ERG and Microperimetry Outcomes of Monthly vs As Needed Ranibizumab in Neovascular Age-Related Macular degeneration (2008)
(GRA)General Research Administrator/(CRC) Clinical research coordinator
Regeneron VIEW1: A Randomized, Double Masked, Active Controlled Phase III Study ofthe Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration (2008)
(GRA)General Research Administrator/(CRC) Clinical research coordinator
Regeneron VIEW1: A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration (2008)
(GRA)General Research Administrator/(CRC) Clinical research coordinator
Alcon GATE: The Safety and Efficacy of AL-8309B Ophthalmic Solution for the Treatment of Geographic Atrophy (GA) Secondary to Age-Related Macular Denegation (AMD) (2009)
(GRA) General Research Administrator/(CRC) Clinical research coordinator
Genentech HARBOR: A Phase III, Double Masked, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of 0.5mg and 2.0mg Ranibizumab Administered Monthly or on an As-Needed Basis (PRN) in Patients with Subfoveal Neovascular Age-Related Macular Degeneration (2009)
(GRA) General Research Administrator/(CRC) Clinical research coordinator
Genentech HORIZON: An open-label, multicenter Extension study to evaluate the safety and tolerability of RANIBIZUMAB in subjects with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) or macular edema secondary to RETINAL VEIN
OCCLUSION (RVO) who have completed a genentech-sponsored RANIBIZUMAB STUDY (2009)
(GRA)General Research Administrator/(CRC) Clinical research coordinator
Alcon ALKOR: C-07-43 – A Clinical Safety and Efficacy Comparison of NEVANAC® 0.1% to Vehicle Following Cataract Surgery in Diabetic Retinopathy Patients (2009)
(GRA)General Research Administrator/(CRC) Clinical research coordinator
Valley Eye Retina PRESERVE: Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease (2009)
(GRA)General Research Administrator/(CRC) Clinical research coordinator
Nepafenac as Adjunctive Therapy for Patients with Clinically Significant Diabetic Macular Edema (2009)
(GRA)General Research Administrator/(CRC) Clinical research coordinator
Regeneron: A Randomized, Double Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of VEGF Trap-Eye in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion (2010)
(GRA)General Research Administrator/(CRC) Clinical research coordinator
Allergan: A 12-Month Multicenter, Masked, Randomized, Controlled Study to Assess the Safety and Efficacy of 700 ug Ozurdex as Adjunctive Therapy to Lucentis Compared with Lucentis Alone in the Treatment of Patients with Choroidal Neovascularization Secondary to Age-related Macular Degeneration (2010)
(GRA)General Research Administrator/(CRC) Clinical research coordinator
Nevanac Ist, Ron Gallemore: Exploratory, Randomized, Controlled Clinical Study Assessing the Efficacy of (2010)
(GRA)General Research Administrator/(CRC) Clinical research coordinator
Quan Nguyen READ3: Ranibizumab for Edema of the Macula in Diabetes; Protocol 3 with High Dose – the READ 3 study (2010)
(GRA)General Research Administrator/(CRC) Clinical research coordinator
Genentech- MAHALO: A Phase IB/II, Multicenter, Randomized, Single-Masked, Sham-Injection-Controlled Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Intravitreal Injections Administered Monthly or Every Other Month to Patients with Geographic Atrophy (2010)
(GRA)General Research Administrator/(CRC) Clinical research coordinator
Genentech-SHORE: A Multicenter, Randomized, Study Evaluating Dosing Regimens for Treatment with Intravitreal Ranibizumab Injections in Subjects with Macular Edema Following Retinal Vein Occlusion (2011)
(GRA)General Research Administrator/(CRC) Clinical research coordinator
Santen: A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study Assessing the Safety and Efficacy of Intravitreal Injections of DE-109 (three doses) for the Treatment of active, Non-Infectious Uveitis of the Posterior Segment of the eye (2011)
(GRA)General Research Administrator/(CRC) Clinical research coordinator
Novartis-CRFB002A2407: A 16-week evaluation of the novartis health management tool in assessing self-test visual function in patients with AMD treated with Lucentis (2011)
(GRA)General Research Administrator/(CRC) Clinical research coordinator
Regeneron- VGFT-OD-1009: A Double-Masked, Randomized, Active- Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular dema (2011)
(GRA)General Research Administrator/(CRC) Clinical research coordinator
Allergan- 1128277 – Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema (2011)
(GRA)General Research Administrator/(CRC) Clinical research coordinator
Allergan BDP208397-001: A 12-Month, Multicenter, 2-Stage (Open Label, Dose Escalation, Followed by Masked, Randomized) Single Dose Study of the Safety and Efficacy of AGN-208397 in Patients with Macular Edema (ME) Associated with Retinal Vein Occlusion (RVO)
(GRA)General Research Administrator/(CRC) Clinical research coordinator
Novartis- CLFG316A2202: A multicenter, multiple dose study to assess the safety, tolerability, serum pharmacokinetics, and efficacy of intravitreal LFG316 in patients with neovascular age-related macular degeneration (2012)
(GRA)General Research Administrator/(CRC) Clinical research coordinator
LUX Biosciences- LX-211-11: A Multi-Center, Double-Masked, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Voclosporin as Therapy in Subjects with Active Noninfectious Uveitis Involving the Intermediate and/or Posterior Segments of the Eye (2012)
(GRA)General Research Administrator/(CRC) Clinical research coordinator
Allergan IST DME IIT-406: a randomized study to test the efficacy of Ozurdex versus Avastin on recalcitrant macular edema and macular function associated with diabetic retinopathy on patients with two or more prior intravitreal anti-VEGF drug injections. (2012)
(GRA)General Research Administrator/(CRC) Clinical research coordinator
Allergan REACH-AGN-150998: A phase 2, randomized, double-masked comparison of the effects and safety of treatment with AGN-150998 and ranibizumab on retinal edema and BCVA in treatment-naïve patients with exudative age-related macular degeneration (AMD). (2012)
(GRA)General Research Administrator/(CRC) Clinical research coordinator
iDEAL- 2010-007-03-DME: A randomized, multi-center, phase 2 study evaluating the safety, tolerability, and bioactivity of repeated intravitreal injections of iCo-007 as monotherapy or in combination with laser photocoagulation or Ranibizumab in adult patients with Diabetic Macular Edema. (2012)
(GRA)General Research Administrator/(CRC) Clinical research coordinator
Alcon- C-10-083: A prospective, double-masked, active-controlled, single dose randomized study to assess the safety, tolerability, and efficacy of ESBA 1008 versus Lucentis in adult patients with exudative age-related macular degeneration (AMD) (2012)